Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNeo-Vac-T01 in Advanced Colorectal Cancer
NCT07504523Phase 1Recruiting
- Sponsor
- Ying Yuan Chemical Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Dec 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iNeo-Vac-T01 in colorectal cancer (CRC), sponsored by Ying Yuan Chemical Pharmaceutical. Primary endpoints: Ratio of patients receiving iNeo-Vac-T01 infusion to total enrolled patients at 36 months and Safety and tolerable dose at 36 months. Started Nov 2023; status: recruiting.
02
Drugs
iNeo-Vac-T01
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07504523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07504523.